Using bioluminescence imaging in glioma research

Rodney B Luwor; Stanley S Stylli; Andrew H Kaye

doi:10.1016/j.jocn.2014.11.001

Using bioluminescence imaging in glioma research

J Clin Neurosci. 2015 May;22(5):779-84. doi: 10.1016/j.jocn.2014.11.001. Epub 2015 Mar 26.

Authors

Rodney B Luwor¹, Stanley S Stylli², Andrew H Kaye²

Affiliations

¹ Department of Surgery, Level 5, Clinical Sciences Building, The University of Melbourne, The Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia. Electronic address: [email protected].
² Department of Surgery, Level 5, Clinical Sciences Building, The University of Melbourne, The Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia; Department of Neurosurgery, The Royal Melbourne Hospital, Parkville, VIC, Australia.

PMID: 25816780
DOI: 10.1016/j.jocn.2014.11.001

Abstract

Glioblastoma multiforme (GBM) is the most common malignant brain tumour and has the worst prognosis. Over the last decade, the use of bioluminescence imaging technology has rapidly become widespread to further understand the mechanisms that drive GBM development and progression. Pre-clinical evaluation and optimisation of therapeutic efficacy in GBM research has also utilised this simple non-invasive technology. Here we summarise recent advances made in glioma biology and therapeutic intervention using bioluminescence imaging. This review also describes the current knowledge regarding the use of luciferase-based reporters in examining the role of specific cancer signalling cascades that promote glioma progression.

Keywords: Bioluminescence; Glioblastoma multiforme; Signalling; Therapy.

Publication types

Review

MeSH terms

Animals
Biomedical Research / methods*
Brain Neoplasms / diagnosis*
Brain Neoplasms / therapy
Diagnostic Imaging / methods
Disease Progression
Glioblastoma / diagnosis
Glioblastoma / therapy
Glioma / diagnosis*
Glioma / therapy
Humans
Luminescent Measurements / methods*